ID Connect’s clinical consultant Erin McCreary, PharmD, BCPS, BCIDP, commented on the demise of Evusheld in Time Magazine’s Feb. 8, 2023, online edition. The article, titled “Without Evusheld, Immunocompromised People Are on Their Own Against COVID-19,” explores the effects of the end of the pandemic emergency declarations in May 2023 and the FDA’s revoked emergency-use authorization of Evusheld, a therapy first authorized in Dec. 2021.
You might also like…
ID Connect Featured in UPMC Enterprises 2024 Year in Review
E. coli Outbreaks and Your Hospital – Prevent an E. coli Emergency
Journal Article – Remote Practice of Infectious Diseases Through Telemedicine: Improving Access for Patients and Appeal for Physicians